Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/4843
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mujugira, Andrew | - |
dc.contributor.author | Magaret, Amalia S. | - |
dc.contributor.author | Celum, Connie | - |
dc.contributor.author | Baeten, Jared M. | - |
dc.contributor.author | Lingappa, Jairam R. | - |
dc.contributor.author | Morrow, Rhoda Ashley | - |
dc.contributor.author | Fife, Kenneth H. | - |
dc.contributor.author | Delany-Moretlwe, Sinead | - |
dc.contributor.author | Were, Edwin | - |
dc.date.accessioned | 2021-07-14T08:20:33Z | - |
dc.date.available | 2021-07-14T08:20:33Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://doi.org/10.1093/infdis/jit333 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/4843 | - |
dc.description.abstract | Background. Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2–serodiscordant heterosexual couples by 48%. Whether suppressive therapy reduces HSV-2 transmission from persons coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) is unknown. Methods. Within a randomized trial of daily acyclovir 400 mg twice daily in African HIV-1 serodiscordant couples, in which the HIV-1–infected partner was HSV-2 seropositive, we identified partnerships in which HIV-1–susceptible partners were HSV-2 seronegative to estimate the effect of acyclovir on risk of HSV-2 transmission. Results. We randomly assigned 911 HSV-2/HIV-1–serodiscordant couples to daily receipt of acyclovir or placebo. We observed 68 HSV-2 seroconversions, 40 and 28 in acyclovir and placebo groups, respectively (HSV-2 incidence, 5.1 cases per 100 person-years; hazard ratio [HR], 1.35 [95% confidence interval, .83–2.20]; P = .22). Among HSV-2–susceptible women, vaginal drying practices (adjusted HR, 44.35; P = .004) and unprotected sex (adjusted HR, 9.91; P = .002) were significant risk factors for HSV-2 acquisition; having more children was protective (adjusted HR, 0.47 per additional child; P = .012). Among HSV-2–susceptible men, only age ≤30 years was associated with increased risk of HSV-2 acquisition (P = .016). Conclusions. Treatment of African HSV-2/HIV-1–infected persons with daily suppressive acyclovir did not decrease risk of HSV-2 transmission to susceptible partners. More-effective prevention strategies to reduce HSV-2 transmission from HIV-1–infected persons are needed. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford University Press | en_US |
dc.subject | Acyclovir | en_US |
dc.subject | Serodiscordant couples | en_US |
dc.subject | HIV-1 transmission | en_US |
dc.subject | HIV-2 transmission | en_US |
dc.title | Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.